Author:
Preston Ioana R.,Hill Nicholas S.
Reference49 articles.
1. Schermuly RT, Roehl A, Weissmann N et al (2000) Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 292:512–520
2. Schermuly RT, Ghofrani HA, Enke B et al (1999) Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 160:1500–1506
3. Schermuly RT, Roehl A, Weissmann N et al (2001) Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 281:L1361–L1368
4. Kuhn KP, Wickersham NE, Robbins IM, Byrne DW (2004) Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res 30:135–145
5. Ghofrani HA, Rose F, Schermuly RT et al (2002) Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 30:2489–2492